Antibodies May Steer Allergies Toward Tolerance
Early lab and mouse results suggest antibody therapy could help people with peanut or tree-pollen allergies, pending human trials.
Updated on Nov. 5, 2026 in Allergies

Swiss biotech Mabylon AG announced a study in Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology, showing that allergen-specific IgG4 antibodies can redirect allergens toward immune cells that promote tolerance. The findings come from experiments with cells from peanut-allergic patients and a mouse model, and are relevant to people living with peanut and tree-pollen allergies.
Why it matters
Current allergy care centers on managing symptoms and, in some cases, gradually building tolerance through immunotherapy, so researchers are looking for ways to change the underlying immune response. This study offers a mechanistic explanation for how IgG4 antibodies might shift that response away from allergy-driving pathways, a step that is newsworthy because it is preliminary and not yet tested in patients.
The findings rest on laboratory experiments with cells from peanut-allergic patients and a mouse model of peanut allergy, not on human clinical outcomes. The mouse results showed reduced mast-cell activation and no rise in allergen-specific IgE during oral immunotherapy, but whether these effects hold in people has not yet been tested.
The players
Mabylon AG
A Swiss biotechnology company developing antibody-based therapies for allergic diseases, including the peanut-allergy candidate MY006 and the tree-pollen candidate MY010.
Clinical & Experimental Allergy
The official journal of the British Society for Allergy & Clinical Immunology, which published the study.
British Society for Allergy & Clinical Immunology
The UK professional society for allergy and clinical immunology specialists, which sponsors the journal that published the research.
The details
Allergen-specific IgG4 antibodies bind to allergens and steer them away from B cells, which produce allergy-driving IgE antibodies, and toward myeloid antigen-presenting cells instead. In cells from peanut-allergic patients, this redirection was linked to lower levels of type 2 inflammatory signals, higher levels of the anti-inflammatory cytokine IL-10, and stronger regulatory T-cell responses. The same allergen-redirection pattern was observed with birch-specific antibodies and the birch pollen allergen Bet v 1.
Timeline
November 5, 2026: Mabylon announced publication of the study in Clinical & Experimental Allergy.
2027: Clinical trials of MY010, a birch and tree-pollen antibody, are expected to begin.
Health Landscape
Oral allergen immunotherapy is an established way of building tolerance to food and pollen allergens, but its effects on the underlying IgE response are a known limitation researchers continue to address. This work positions antibody-based approaches as a potential complement to immunotherapy, though it remains at the laboratory and mouse-model stage.
If you or a family member have a peanut or tree-pollen allergy, this research is an early signal rather than a new treatment you can access now. It is worth raising with your allergist as a question about emerging therapies and clinical trial options rather than a reason to change current management.
The takeaway
Antibody-based approaches may one day help the immune system develop tolerance to allergens more reliably, but these results are preliminary and drawn from lab and animal work. If you are interested in future options, ask your allergist whether any clinical trials for peanut or pollen allergy are open to you.
What happens next
Clinical trials of MY010 are expected to start in 2027, and results from ongoing studies will determine whether these tolerance effects translate into patient benefit.
Further reading
For background on how these conditions are managed, explore our Allergies coverage.
Source note: This article includes information reported by Pharmabiz.


